Prospective surveillance of intravenous amphotericin B use patterns.

Abstract:

:Information on amphotericin B use patterns and infusion-related adverse events were prospectively collected from 397 hospitalized adults. The methods of initiating amphotericin B varied greatly, with the majority of patients being gradually titrated to a full maintenance dose over 1-5 days. Overall, 71% of patients experienced at least one episode of an infusion-related adverse event (IRAE) during the first week of therapy. Fever and chills were most commonly observed, with peak frequency on days 1-3, followed by a subsequent decline. A wide variety of pretreatment medications were used to minimize IRAE; the most common regimens included some combination of diphenhydramine, acetaminophen, and corticosteroids, with or without heparin. The majority of patients (84.7%) received a test dose, and although none experienced a severe allergic reaction, one patient subsequently had an anaphylactic episode on the third day of amphotericin B therapy. The use of a test dose and the titration process are attempts to avoid the IRAE frequency associated with large initial doses of amphotericin B, but we observed that they provided little or no benefit. In addition, our study suggests that pretreatment regimens are frequently used in conjunction with the test dose. If the intent of the test dose is to identify patients sensitive to amphotericin B, pretreatment drugs may minimize these adverse events and prevent a complete evaluation of response to the test dose.

journal_name

Pharmacotherapy

journal_title

Pharmacotherapy

authors

Grasela TH Jr,Goodwin SD,Walawander MK,Cramer RL,Fuhs DW,Moriarty VP

subject

Has Abstract

pub_date

1990-01-01 00:00:00

pages

341-8

issue

5

eissn

0277-0008

issn

1875-9114

journal_volume

10

pub_type

临床试验,杂志文章,多中心研究,评审
  • Low-dose botulinum toxin type A for the treatment of refractory piriformis syndrome.

    abstract:STUDY OBJECTIVES:To evaluate the efficacy of a single, low-dose injection of botulinum toxin type A in relieving pain in Korean patients with piriformis syndrome resistant to conventional therapy, and to assess the drug's influence on these patients' quality of life. DESIGN:Prospective, single-site, open-label trial. ...

    journal_title:Pharmacotherapy

    pub_type: 临床试验,杂志文章

    doi:10.1592/phco.27.5.657

    authors: Yoon SJ,Ho J,Kang HY,Lee SH,Kim KI,Shin WG,Oh JM

    更新日期:2007-05-01 00:00:00

  • Intravenous amiodarone for conversion of atrial fibrillation: misled by meta-analysis?

    abstract::Therapeutic goals for atrial fibrillation (AF) include ventricular rate control, stroke prevention, conversion to normal sinus rhythm, and maintenance of normal sinus rhythm. The optimal strategy of rate versus rhythm control for acute management of patients with AF is a continuing debate. However, selected patients m...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.24.8.792.36065

    authors: Slavik RS,Zed PJ

    更新日期:2004-06-01 00:00:00

  • Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.

    abstract:STUDY OBJECTIVE:To evaluate the safety and efficacy of valganciclovir 450 mg/day for 6 months for cytomegalovirus (CMV) prophylaxis in renal transplant recipients. DESIGN:Single-center, retrospective analysis. SETTING:Urban, academic medical center. PATIENTS:Fifty-eight patients who received de novo renal transplant...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1592/phco.24.14.1323.43152

    authors: Gabardi S,Magee CC,Baroletti SA,Powelson JA,Cina JL,Chandraker AK

    更新日期:2004-10-01 00:00:00

  • Pharmacologic Considerations for Solid Organ Transplant Recipients Who Become Pregnant.

    abstract::Females of childbearing age represent a large population of solid organ transplant recipients. With fertility commonly restored after transplantation, the possibility of pregnancy becomes a reality for many patients. Since the first published report of a successful pregnancy after solid organ transplantation in 1963, ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1002/phar.1800

    authors: Casale JP,Doligalski CT

    更新日期:2016-09-01 00:00:00

  • Can garlic lower blood pressure? A pilot study.

    abstract::A popular garlic preparation containing 1.3% allicin at a large dose (2400 mg) was evaluated in this open-label study in nine patients with rather severe hypertension (diastolic blood pressure > or = 115 mm Hg). Sitting blood pressure fell 7/16 (+/- 3/2 SD) mm Hg at peak effect approximately 5 hours after the dose, wi...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:

    authors: McMahon FG,Vargas R

    更新日期:1993-07-01 00:00:00

  • Warfarin and royal jelly interaction.

    abstract::An 87-year-old African-American man came to the internal medicine clinic for a routine anticoagulation management visit. He had no complaints. His medical history was significant for stage IV-A follicular non-Hodgkin's lymphoma, atrial fibrillation, and hypertension. His long-term drug therapy consisted of warfarin, f...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1592/phco.26.4.583

    authors: Lee NJ,Fermo JD

    更新日期:2006-04-01 00:00:00

  • Nonhormonal alternatives for the treatment of hot flashes.

    abstract:OBJECTIVE:To review the literature on clonidine, venlafaxine, selective serotonin reuptake inhibitors, and gabapentin for the treatment of hot flashes. DATA SOURCES:A MEDLINE search (January 1966-July 2003) was conducted to identify English-language literature available on the treatment of hot flashes that focused on ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.24.1.79.34812

    authors: Sicat BL,Brokaw DK

    更新日期:2004-01-01 00:00:00

  • Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing.

    abstract::Patients with various rheumatologic and inflammatory disease states commonly require drugs known to decrease the inflammatory or autoimmune response for adequate control of their condition. Such drugs include nonsteroidal antiinflammatory drugs (NSAIDs), cyclooxygenase (COX)-2 inhibitors, corticosteroids, disease-modi...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.2005.25.11.1566

    authors: Busti AJ,Hooper JS,Amaya CJ,Kazi S

    更新日期:2005-11-01 00:00:00

  • Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.

    abstract:STUDY OBJECTIVES:To examine glycosylated hemoglobin (A1C) values longitudinally in patients who newly started metformin, sulfonylurea, or thiazolidinedione monotherapy; in a subset of patients whose A1C values were 7% or greater before starting therapy (baseline) and who achieved A1C goal (A1C < 7%) during therapy, rat...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1592/phco.27.8.1102

    authors: Riedel AA,Heien H,Wogen J,Plauschinat CA

    更新日期:2007-08-01 00:00:00

  • An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria.

    abstract::Stenotrophomonas maltophilia, Burkholderia cepacia complex, Elizabethkingia spp., Chryseobacterium spp., Achromobacter spp., and Alcaligenes spp. are less-common non-lactose-fermenting bacteria that have emerged as important opportunistic pathogens. Patients at the highest risk for these infections include the immunoc...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1002/phar.2447

    authors: Spencer HK,Spitznogle SL,Borjan J,Aitken SL

    更新日期:2020-09-01 00:00:00

  • Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes.

    abstract:STUDY OBJECTIVE:To determine the effect of Niaspan--a niacin preparation with both immediate- and extended-release characteristics--on lipid and glycemic control in patients with type 2 diabetes. DESIGN:Retrospective study SETTING:Private-practice endocrinology group. PATIENTS:Thirty-two patients (mean age 60 yrs; 7...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1592/phco.21.20.1473.34481

    authors: Kane MP,Hamilton RA,Addesse E,Busch RS,Bakst G

    更新日期:2001-12-01 00:00:00

  • Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage.

    abstract::Aneurysmal subarachnoid hemorrhage (SAH) accounts for a significant percentage of morbidity and mortality among patients admitted to neurosurgical centers throughout the world. Even for individuals surviving beyond the initial presentation and intervention for aneurysmal SAH, the occurrence of cerebral vasospasm has t...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.30.4.405

    authors: Weant KA,Ramsey CN 3rd,Cook AM

    更新日期:2010-04-01 00:00:00

  • Sudden irreversible sensory-neural hearing loss in a patient with diabetes receiving amikacin as an antibiotic-heparin lock.

    abstract::Gram-negative septicemia due to central venous catheter-related infection is a leading cause of mortality and morbidity among patients who undergo hemodialysis. Antibiotic-heparin locks are valuable for preserving access sites and lowering the cost and inconvenience associated with central venous catheter replacement ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1592/phco.22.1.105.33507

    authors: Saxena AK,Panhotra BR,Naguib M

    更新日期:2002-01-01 00:00:00

  • Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?

    abstract::The era of the integrase strand transfer inhibitors (INSTIs) for the treatment of human immunodeficiency virus (HIV) infection began with raltegravir in 2007. Since that time, several other INSTIs have been introduced including elvitegravir, dolutegravir, and, most recently, bictegravir, that have shown great utility ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1002/phar.2246

    authors: Brooks KM,Sherman EM,Egelund EF,Brotherton A,Durham S,Badowski ME,Cluck DB

    更新日期:2019-05-01 00:00:00

  • Acetaminophen-related acute renal failure without fulminant liver failure.

    abstract:BACKGROUND:Our patient experienced acute renal failure but not fulminant hepatic failure from acetaminophen toxicity. OBJECTIVE:To review the clinical and laboratory characteristics of similar cases of acetaminophen nephrotoxicity. METHODS:A MEDLINE search and medical record search at two large teaching hospitals. R...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:

    authors: Eguia L,Materson BJ

    更新日期:1997-03-01 00:00:00

  • Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy.

    abstract:OBJECTIVE:Assess the effects of linezolid on hematologic outcomes in newly diagnosed patients with acute myeloid leukemia (AML) following induction chemotherapy. DESIGN:Single-center, retrospective, observational, cohort study. SETTING:Large, tertiary care academic medical center. PATIENTS:A total of 225 patients ≥ ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1002/phar.1824

    authors: Nedved AN,DeFrates SR,Hladnik LM,Stockerl-Goldstein KE

    更新日期:2016-10-01 00:00:00

  • Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis.

    abstract::We conducted a systematic review of randomized, controlled, monotherapy trials since 1990 of oral antihypertensive agents in patients with essential hypertension. Our objective was to quantify the frequency of discontinuation of antihypertensive agents due to adverse events from a meta-analysis of the studies. A total...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,meta分析

    doi:10.1592/phco.21.11.940.34520

    authors: Ross SD,Akhras KS,Zhang S,Rozinsky M,Nalysnyk L

    更新日期:2001-08-01 00:00:00

  • Identification of a gemcitabine-warfarin interaction.

    abstract::A man anticoagulated with warfarin 57.5 mg/week (international normalized ratio [INR] 1.94) was diagnosed with nonsmall cell lung cancer and prescribed weekly gemcitabine. With the first dose of the first cycle, his INR rose to 3.52, and his weekly warfarin dose was decreased to 52.5 mg. The lower warfarin dose was co...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1592/phco.19.16.1331.30873

    authors: Kinikar SA,Kolesar JM

    更新日期:1999-11-01 00:00:00

  • Changing oral contraceptives from prescription to over-the-counter status: an opinion statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy.

    abstract::Addressing the issue of unintended pregnancy is a national priority. One proposed strategy to reduce unintended pregnancy is to improve access to oral contraceptives by changing them to over-the-counter (OTC) status. Existing data indicate that oral contraceptives meet safety criteria required of OTC products. Availab...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1592/phco.31.4.424

    authors: McIntosh J,Rafie S,Wasik M,McBane S,Lodise NM,El-Ibiary SY,Forinash A,Kachlic MD,Rowe E,Besinque K

    更新日期:2011-04-01 00:00:00

  • Clinical pharmacology of recombinant human erythropoietin (r-HuEPO).

    abstract::Recombinant human erythropoietin reverses the severe anemia associated with end-stage renal disease. Mean half-life values after a single intravenous bolus dose range from 4-13 hours. Renal clearance is not a significant route of elimination. Dosing schedules in chronic renal failure involve a single intravenous bolus...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:

    authors: Flaharty KK

    更新日期:1990-03-01 00:00:00

  • Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis.

    abstract:STUDY OBJECTIVE:To evaluate the success of an initial tobramycin dosing regimen to achieve target peak and trough concentrations in adult patients with pulmonary exacerbations of cystic fibrosis (CF). DESIGN:Retrospective single-center medical record review. SETTING:Large tertiary care academic medical center. PATIE...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1002/phar.1762

    authors: Staubes BA,Metzger NL,Walker SD,Peasah SK

    更新日期:2016-06-01 00:00:00

  • Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease.

    abstract::Acute graft-versus-host disease (GVHD) remains the major obstacle for successful allogeneic bone marrow transplantation (BMT). The frequency of grade II or higher acute GVHD ranges from 30-50% in human leukocyte antigen (HLA)-matched sibling transplants and 50-80% in HLA-matched unrelated transplants. The mortality an...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:

    authors: Tse JC,Moore TB

    更新日期:1998-09-01 00:00:00

  • Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.

    abstract::Antiretroviral (ART) therapy for the treatment of human immunodeficiency virus (HIV) infection has undergone significant changes over the past 30 years. Many single-tablet regimens (STRs), including newer fixed-dose combination (FDC) tablets, are available, offering patients several options for choosing a treatment re...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1002/phar.2055

    authors: McCoy C,Badowski M,Sherman E,Crutchley R,Smith E,Chastain DB,Society of Infectious Diseases Pharmacists.

    更新日期:2018-01-01 00:00:00

  • Alprazolam in bipolar-I depressions.

    abstract::In an open-label study of alprazolam in five bipolar-I depressed patients, three patients remitted completely, one failed to respond, and one responded transiently, based on the Hamilton Rating Scale and Beck Depression Inventory scores. Further studies of alprazolam as an antidepressant are warranted. ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1002/j.1875-9114.1984.tb03311.x

    authors: Rush AJ,Schlesser MA,Erman M,Fairchild C

    更新日期:1984-01-01 00:00:00

  • Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents.

    abstract::Endothelin (ET)-1 is an endothelium-derived peptide with potent vasoconstrictor and proliferative properties. The ET system is activated in several cardiovascular disease states associated with functional and structural vascular changes, including hypertension and heart failure. The two ET receptor subtypes are known ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1592/phco.22.1.54.33505

    authors: Ergul A

    更新日期:2002-01-01 00:00:00

  • Postoperative atrial fibrillation: role of inflammatory biomarkers and use of colchicine for its prevention.

    abstract::Postoperative atrial fibrillation (POAF) is the most common complication following cardiac surgery, occurring in up to 65% of cardiac surgical patients. It is a condition associated with increased morbidity, increased length of hospital stay, and increased health care costs. One of the many potential causes of POAF is...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1002/phar.1485

    authors: Worden JC,Asare K

    更新日期:2014-11-01 00:00:00

  • Spontaneous Hemopericardium in a Patient Receiving Apixaban Therapy: First Case Report.

    abstract::Apixaban, a direct factor Xa inhibitor, is a novel oral anticoagulant (NOAC) indicated for prevention of embolic events in patients with nonvalvular atrial fibrillation. The agent is associated with a lower risk of bleeding compared with vitamin K antagonists such as warfarin. Hemopericardium is a life-threatening ble...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:10.1002/phar.1602

    authors: Sigawy C,Apter S,Vine J,Grossman E

    更新日期:2015-07-01 00:00:00

  • Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.

    abstract::The antiretroviral combination of emtricitabine-tenofovir disoproxil fumarate (FTC/TDF) was approved by the U.S. Food and Drug Administration for use as pre-exposure prophylaxis (PrEP) in individuals at high risk for acquiring human immunodeficiency virus (HIV) in July 2012. Since then, Centers for Disease Control and...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1002/phar.2240

    authors: Adams JL,Shelley K,Nicol MR

    更新日期:2019-04-01 00:00:00

  • Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.

    abstract::Health care-associated infections, especially those caused by multidrug-resistant gram-positive organisms, such as methicillin-resistant Staphylococcus aureus (MRSA), are a growing public health threat. In 2014, the U.S. Food and Drug Administration approved two new lipoglycopeptides, oritavancin and dalbavancin, for ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1002/phar.1641

    authors: Roberts KD,Sulaiman RM,Rybak MJ

    更新日期:2015-10-01 00:00:00

  • Antimicrobial formulary management: a case study in a teaching hospital.

    abstract::The role of the formulary system for effective cost containment is becoming increasingly important. With antimicrobial agents taking up a large proportion of most pharmaceutical budgets, this group of agents is an obvious target for cost reduction. The responsible interchange of selected antimicrobial agents offers a ...

    journal_title:Pharmacotherapy

    pub_type: 杂志文章

    doi:

    authors: Wright DB

    更新日期:1991-01-01 00:00:00